Pharmafile Logo

Duchenne muscular distrophy

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

- PMLiVE

Alcon wins initial NICE backing for Jetrea in rare eye condition

Would be first alternative to surgery available to vitreomacular traction patients in England and Wales

National Institute for Health and Care Excellence NICE logo

NICE U-turn on GSK’s Revolade

Watchdog says yes to blood disorder drug three years after initial knockback

National Institute for Health and Care Excellence NICE logo

NICE backs Abilify for teenagers with bipolar disorder

Otsuka's antisphycotic recommended for use in adolescents in England and Wales

- PMLiVE

Eylea set to challenge Lucentis in UK after NICE recommendation

Bayer’s medicine recommended for NHS use to treat wet AMD

National Institute for Health and Care Excellence NICE logo

NICE reverses negative guidance for Forxiga in diabetes

Final draft guidance backs the use of BMS/AstraZeneca’s SGLT-2 inhibitor in certain patients

- PMLiVE

Novartis wins third NICE recommendation for Lucentis

Gains final backing to treat NHS patients with macular oedema

National Institute for Health and Care Excellence NICE logo

NICE recommends Astellas’ Betmiga for overactive bladder

Final draft guidance recommends Vesicare successor

Former NICE chair joins board of biotech

Sir Michael Rawlins joins board of Intra-Cellular Therapeutics

- PMLiVE

Value-based pricing “not in patient interest”

Think-tank 2020health calls for rethink of UK drug pricing plans

- PMLiVE

NICE tasked with speeding NHS uptake of new technology

Expanded role will see it takeover the work of the NHS Technology Adoption Centre

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links